prediction, page-9

"Out comes akki and just talks about atl 1103...,.forgetting the other 2...lol"

ItsGAS - yes ATL-1103 is the focus the other 2 one still remains pre-clinical & the other the path is yet to be determined if assuming the JV does come through it's still going to take time for progression to be made your $600M call in 2 years is ummmmmmmmmm i dont have to say it do i ? lol

Multiple candidates don't neccesarily translate into higher prices in the short term but they balance risk - if you have more in the clinic then should one fail the impact can be rubbed off with focus then put into the others. NEU as an example being another penny stock has 2x Phase II Trials of the lead candidate targeting different areas a 3rd Phase II trial with Motiva, a 4th prelinical & 5th antibody preclinical - $50M mc.